AtheroGenics Added to NASDAQ Biotech Index ATLANTA, Nov. 14 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. , a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it has been selected to be added to the NASDAQ Biotechnology Index effective with the market open on Monday, November 24, 2003. All securities in the Index are listed on the NASDAQ National Market and must be classified according to the FTSE Global Classification System as either biotechnology or pharmaceutical. In addition, all securities in the Index must meet minimum requirements for price, market value, average daily share volume and seasoning as a public company. The Index is ranked on a semi-annual basis in May and November. About AtheroGenics AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including heart disease (atherosclerosis), rheumatoid arthritis and asthma. The Company has four drug development programs in the clinic. AtheroGenics' lead compound, AGI-1067, is being evaluated in the pivotal Phase III clinical trial called ARISE (Aggressive Reduction of Inflammation Stops Events) as an oral therapy for the treatment of atherosclerosis. AGIX-4207, the Company's second clinical compound derived from its proprietary v- protectant(TM) technology platform, is a novel, oral agent being tested in a Phase II clinical program called OSCAR (Oral Suppression of Cellular Inflammation Attenuates Rheumatoid Arthritis) as an oral therapy for the treatment of rheumatoid arthritis. AGIX-4207 I.V. is an intravenous rheumatoid arthritis treatment that has completed a Phase I clinical study. AGI-1096 is a novel, oral agent that has completed a Phase I clinical trial for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com/ . This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements which address operating performance, events or developments that we expect or anticipate will occur in the future, such as projections about our future results of operations or our financial condition, research, development and commercialization of our product candidates, anticipated trends in our business, and other risks that could cause actual results to differ materially. These risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including but not limited to the risks discussed in AtheroGenics' Form 10-K for fiscal 2002 and our Quarterly Report on Form 10-Q for the second quarter of 2003. DATASOURCE: AtheroGenics, Inc. CONTACT: Donna Glasky, Corporate Communications of AtheroGenics, Inc., +1-678-336-2517, or ; or Lilian Stern, of Stern Investor Relations, +1-212-362-1200, or ; or Katie Brazel, Media Relations of Fleishman Hillard, +1-404-739-0150, or Web site: http://www.atherogenics.com/

Copyright